Ginsenoside Re
Catalog No: CFN99974
Ginsenoside Re is a major ginsenoside in ginseng and belongs to 20(S)-protopanaxatriol group. It has diverse in vitro and in vivo effects, including anti-diabetic, vasorelaxant, antihyperlipidemic, anti-ischemic, angiogenic, antioxidant, and anti-inflammation actions. It also exhibits potent neuroprotective effects against neuroinflammation in a murine model of ALS. Re increases HCAEC outward current via SKCa channel activation; it also increases the proliferation of CD4+ T cells with decreases cell death, and enhances viability of CD4+T cells through the regulation of IFN-γ-dependent autophagy activity.
Ginsenoside Rf
Catalog No: CFN99976
Ginsenoside Rf is a trace component of ginseng root, which has antinociception, analgesia, anti-inflammatory, and anti-cancer activities, it induces G2/Mphase cell cycle arrest and apoptosis in human osteosarcoma MG-63 cells through the mitochondrial pathway. Rf can act through a novel G protein-linked receptor in the nervous system by inhibiting N-type Ca2+ channel. Rf significantly reduces the production of IL-1β, IL-6, TNF-α, NO, and ROS, and suppresses TNF-α/LPS-induced NF-κB transcriptional activity.
Ginsenoside Rg1
Catalog No: CFN99967
Ginsenoside Rg1 has antiaging, anti-platelet activation, promotion of wound healing, and neuroprotective effects, it has protective effect against Aβ25-35-induced toxicity in PC12 cells,might be through the insulin-like growth factor-I receptor (IGF-IR) and estrogen receptor (ER)signaling pathways. Ginsenoside Rg1 is a desirable agent for enhancing CD4+ T-cell activity, as well as the correction of Th1-dominant pathological disorders, which by increasing Th2 specific cytokine secretion and by repressing Th1 specific cytokine production. It increased the expression of the vascular endothelial growth factor (VEGF) mRNA and reduced ERK pathway, expression of transforming growth factor beta (TGF-β) mRNA.
Ginsenoside Rg3
Catalog No: CFN99969
Ginsenoside Rg3 is the main component of Red ginseng, it inhibits Na+ and hKv1.4 channel with IC50s of 32.2±4.5 and 32.6±2.2 μM, respectively, it also inhibits Aβ levels, NF-κB activity, and COX-2 expression. Ginsenoside-Rg3 possesses an ability to inhibit the lung metastasis of tumor cells, and the mechanism of its antimetastatic effect is related to inhibition of the adhesion and invasion of tumor cells, and also to anti-angiogenesis activity. It is a novel drug, capable of inhibiting the early of scarring (HS) and later HS.
Ginsenoside Rh1
Catalog No: CFN99970
Ginsenoside Rh1 has anti-obesity, anti-inflammatory, antiallergic, and anti-tumor activities, it may improve glucocorticoid efficacy in hormone-dependent diseases.
It inhibits MAPK and PI3K/Akt signaling pathways and downstream transcription factors such as NF-κB and AP-1, which play an important role in MMP gene expressions; it also inhibits IFN-gamma-induced JAK/STAT and ERK signaling pathways and downstream transcription factors, and thereby iNOS gene expression.
Ginsenoside Rh3
Catalog No: CFN99972
Ginsenoside Rh3 is a bacterial metabolite of Ginsenoside Rg5, Rh3 has anti-inflammatory effect in microglia by modulating AMPK and its downstream signaling pathways, it may improve chronic dermatitis or psoriasis by the regulation of IL-1β and TNF-α produced by macrophage cells and of IFN-γ produced by Th cells. Rg5 and Rh3 inhibited acetylcholinesterase activity in a dose-dependent manner, with IC50 values of 18.4 and 10.2 uM, respectively, they may protect memory deficit by inhibiting AChE activity and increasing BDNF expression and CREB activation.
